- Conditions
- Solid Tumor, NSCLC
- Interventions
- JAB-3312, Binimetinib, Pembrolizumab, Sotorasib, Osimertinib
- Drug
- Lead sponsor
- Allist Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 15
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 12 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 52
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Healthy Participants
- Interventions
- AMG 510, Omeprazole, Famotidine
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Healthy Participants
- Interventions
- AMG 510, Digoxin
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Daytona Beach, Florida
- Conditions
- Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Malignant Solid Neoplasm, Malignant Female Reproductive System Neoplasm, Metastatic HER2-Negative Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Malignant Female Reproductive System Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Unresectable HER2-Negative Breast Carcinoma, Unresectable Malignant Solid Neoplasm
- Interventions
- Alpelisib, Binimetinib, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Computed Tomography, Echocardiography Test, Fluorouracil, Fulvestrant, Ipatasertib, Leucovorin, Magnetic Resonance Imaging, Multigated Acquisition Scan, Mutation Carrier Screening, Neratinib Maleate, Nilotinib Hydrochloride Monohydrate, Olaparib, Oxaliplatin, Paclitaxel, Palbociclib, Panitumumab, Positron Emission Tomography, Selumetinib Sulfate, Sotorasib
- Drug · Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 2,900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 478
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 354 more
- Conditions
- Healthy Subjects
- Interventions
- AMG 510
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
- Interventions
- Biopsy, Biospecimen Collection, Carfilzomib, Computed Tomography, Echocardiography, Magnetic Resonance Imaging, Sotorasib
- Procedure · Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 2
- States / cities
- Duarte, California • Irvine, California
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- FOLFIRI Regimen, Sotorasib, Panitumumab, Bevacizumab-awwb
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 26
- States / cities
- Chandler, Arizona • Fullerton, California • Long Beach, California + 21 more
- Conditions
- Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
- Interventions
- Adagrasib, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine, Sotorasib
- Drug · Procedure · Biological
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Healthy Participants
- Interventions
- Sotorasib
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 145 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- Daytona Beach, Florida • Dallas, Texas
- Conditions
- Non Small Lung Cancer
- Interventions
- Sotorasib
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- KRAS p.G12C Mutant Advanced Solid Tumors
- Interventions
- sotorasib, Anti PD-1/L1, Midazolam
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 713 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 39
- States / cities
- Duarte, California • Los Angeles, California • San Francisco, California + 29 more
- Conditions
- Advanced Non-squamous Non-small-cell Lung Cancer
- Interventions
- ERAS-007, ERAS-601, Osimertinib, Sotorasib
- Drug
- Lead sponsor
- Erasca, Inc.
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 11
- States / cities
- Duarte, California • Orange, California • Santa Monica, California + 7 more
- Conditions
- Advanced Solid Tumor
- Interventions
- NB004 tablets
- Drug
- Lead sponsor
- Ningbo Newbay Technology Development Co., Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 2
- States / cities
- New Orleans, Louisiana • Houston, Texas
- Conditions
- Non-Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Solid Tumor
- Interventions
- Inlexisertib, Trametinib, Binimetinib, Sotorasib
- Drug
- Lead sponsor
- Deciphera Pharmaceuticals, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 10
- States / cities
- Boston, Massachusetts • St Louis, Missouri • New Brunswick, New Jersey + 7 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Durvalumab, Sotorasib
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 10
- States / cities
- Miami, Florida • Ann Arbor, Michigan • Basking Ridge, New Jersey + 7 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Sotorasib
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Duarte, California + 20 more
- Conditions
- Healthy Participants
- Interventions
- Sotorasib
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 146 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 4
- States / cities
- Daytona Beach, Florida • South Miami, Florida • Dallas, Texas + 1 more
- Conditions
- Thoracic Tumors, Non-small Cell Lung Cancer
- Interventions
- Anvumetostat, Carboplatin, Paclitaxel, Pembrolizumab, Pemetrexed, Sotorasib
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 26
- States / cities
- Bakersfield, California • Duarte, California • Los Angeles, California + 20 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- VIC-1911, sotorasib
- Drug
- Lead sponsor
- Vitrac Therapeutics, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 5
- States / cities
- Sacramento, California • North Haven, Connecticut • Atlanta, Georgia + 2 more
- Conditions
- Healthy Participants
- Interventions
- AMG 510
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Daytona Beach, Florida
- Conditions
- Healthy Volunteers
- Interventions
- Omeprazole, Sotorasib
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Non Small Cell Lung Cancer, KRAS Activating Mutation
- Interventions
- avutometinib and sotorasib, avutometinib and sotorasib and defactinib
- Drug
- Lead sponsor
- Verastem, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 20
- States / cities
- Boulder, Colorado • Washington D.C., District of Columbia • Arlington Heights, Illinois + 16 more
- Conditions
- Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
- Interventions
- Divarasib, Sotorasib, Adagrasib
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 338 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 25
- States / cities
- Gilbert, Arizona • Los Angeles, California • San Francisco, California + 21 more
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- AMG 510, MVASI
- Drug
- Lead sponsor
- Criterium, Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee